ScholarWorks@Hanyang University: Kim, Tae Hwan

Detailed Information

Kim, Tae Hwan (김태환)

서울 의과대학 (DEPARTMENT OF INTERNAL MEDICINE)

Research Area: 류마티스내과

Tel 02-2290-9216
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Ankylosing spondylitis:62||ankylosing spondylitis:29||Rheumatoid arthritis:28||ankylosing:10||ANKYLOSING SPONDYLITIS:8||Arthritis:8||radiographic progression:8||polymorphism:7||spondylitis:7||Microarray:6||Spondylitis:6||Infliximab:5||Safety:5||s disease:5||genetic:5||HLAB27:5||Korea:5||Inflammation:5||rheumatoid:4||new bone formation:4||Spondyloarthritis:4||DKK1:4||Uveitis:4||Osteoclast:4||tumor necrosis factor inhibitor:4||Disease activity:4||inflammation:4||Treatment:4||rheumatoid arthritis:4||Interstitial lung disease:4||Macrophages:4||Rheumatoid:4||mSASSS:3||SINGLENUCLEOTIDE POLYMORPHISM:3||Osteoprogenitors:3||Osteoporosis:3||magnetic resonance imaging:3||Axial spondyloarthritis:3||HLADRB1:3||ossification of posterior longitudinal ligament:3||osteoporosis:3||Polymorphism:3||AS:3||arthritis:3||peripheral arthritis:3||Polymyositis:3||Epidemiology:3||Synovial fluid:3||biological therapy:3||Quality of life:3||TNF inhibitor:3||spondyloarthritis:3||TREM1:3||Tacrolimus:3||treatment:3||tumor necrosis factor inhibitors:3||enthesitis:3||Osteoclasts:3||Tumor necrosis factor:3||Tumor necrosis factor inhibitor:3||prevalence:2||biologics:2||Synovial macrophages:2||Etanercept:2||Monocytes:2||Mortality:2||Behcet&apos:2||age:2||radiography:2||Dermatomyositis:2||BuddChiari syndrome:2||Gout:2||adultonset Still&apos:2||mineralization:2||Facet joint:2||microRNA:2||Sarcoidosis:2||Bioinformatics:2||RANK:2||etanercept:2||Inflammatory myopathy:2||Discordance:2||Autoimmune disease:2||강직척추염:2||Bone:2||Creactive protein:2||Osteoblast differentiation:2||Radiography:2||systemic:2||infliximab:2||C/EBP beta:2||Ankylosing:2||therapeutics:2||Ankylosing Spondylitis:2||CFHR5:2||Immune response:2||AntiTNFα:2||Tumor necrosis factor blocker:2||Atrial fibrillation:2||osteoblasts:2||MicroRNA:2||Th17 cell:2||Acute myocardial infarction:2||tuberculosis:2||Curdlaninjected SKG mice:2||ankylosing spondylitis (AS):2||Risk factors:2||Ankylosing spodylitis:2||ixekizumab:2||Bonederived cells:2||Rheumatic disease:2||Modified Stoke Ankylosing Spondylitis Spinal Score:2||Prevalence:2||Surveys and questionnaires:2||CTP13:2||Prognosis:2||Hepatitis B virus:2||uveitis:2||Uric acid:2||Expression:1||F18fluoride:1||Fat fraction:1||Fatigue:1||Fracture:1||Fracture healing:1||Fractures:1||Frequency:1||GENETIC RISK SCORING:1||GWAS:1||Gastrointestinal diseases:1||Gender:1||Genetic:1||Golimumab:1||HAQ:1||HAQDI:1||HEPATITIS B VIRUS:1||HLA:1||HLAB27:1||HOUSEHOLD:1||HOXD gene:1||Healthrelated quality of life:1||Healthcare cost:1||Heel pain:1||Hematoma:1||Hemorrhage:1||Homozygosity:1||Human bonederived cells:1||Humanized:1||Hypertrophic chondrocytes:1||Hyperuricemia:1||Hypouricemia:1||IL1 beta:1||IL16:1||IL17 inhibitor:1||IL17 receptor A:1||IL17A:1||IL23:1||IL6:1||IL23R:1||Immunochip:1||Immunosuppression:1||Inactive disease:1||Incidence:1||Inflammationmediated ectopic bone formation:1||Inflammatory bowel disease:1||Inflammatory cytokines:1||Infliximab biosimilar:1||InterferonGamma Release Assay:1||Interleukin 17A:1||Interleukin18:1||Interleukin32:1||Interleukins:1||International Index of Erectile Function:1||Interstitial:1||Intervention:1||Isoniazid:1||JAK2/STAT3 signaling:1||Janus kinase inhibitor:1||Joint range of motion:1||Juvenile ankylosing spondylitis:1||Juvenile idiopathic arthritis:1||Juvenile rheumatoid arthritis:1||Juvenileonset ankylosing spondylitis:1||KOREA:1||Kidney function tests:1||Korean:1||Kynurenine:1||Late onset:1||Latent Tuberculosis Infection:1||Latent tuberculosis:1||Leflunomide:1||Life style:1||Lobular panniculitis:1||Longterm outcome:1||Loss of anterior concavity:1||Lower back pain:1||Lung:1||Lung diseas:1||Lupus erythematosus, Systemic:1||MCSF:1||MEFV:1||MODIFIED STOKE ANKYLOSING SPONDYLITIS SPINE SCORE:1||MSASSS:1||MYCOBACTERIUM TUBERCULOSIS:1||MYH2:1||Magnetic resonance image:1||Magnetic resonance imaging:1||Malignancy:1||Mapping:1||Matrix metalloproteinase:1||Matrix mineralization:1||Microscopic polyangiitis:1||Mineralization:1||Mineralization/calcification:1||Mobility:1||Modified Stoke Ankylosing Spondylitis Spine Score:1||Monoclonal:1||NLRP3 (Nodlike receptor family pyrin domain containing 3:1||NSAID:1||Network analysis:1||Neurological manifestation:1||Nonsteroidal antiinflammatory drugs:1||OCCULT INFECTION:1||OSTEOCLAST:1||Ossification:1||Ossification of posterior longitudinal ligament:1||Osteoarthritis:1||Osteoblastic activity:1||Osteoblastic activity and differentiation:1||Osteoblastic differentiation:1||Osteoblasts:1||Osteoblasts activity:1||Osteoblasts differentiation:1||Osteoclastogenesis:1||Osteoporotic vertebral fracture:1||Osteoprogenitor cells:1||Osteoprotegerin:1||Osteotomy:1||PDGFB/PDGFRB SIGNALING:1||PERIPHERAL ARTHRITIS:1||PERIPHERAL SPONDYLOARTHRITIS:1||PET/CT:1||PRDM10:1||PSORIATIC ARTHRITIS:1||Pain:1||Pathological bone features:1||Pathological bone formation:1||Patient global assessment:1||Peripheral arterial disease:1||Peripheral arthritis:1||Physician global assessment:1||Plain radiography:1||Pneumomediastinum:1||Polygammaglutamic acid (gammaPGA):1||Polymyalgia Rheumatica:1||Polyneuropathy:1||Postmarketing product surveillance:1||Predictor:1||Promoter:1||Proteoglycan:1||Proteomics:1||Psoriatic:1||Psoriatic arthritis:1||Pulmonary function tests:1||Pulse wave velocity:1||QuantiFERONTB gold in tube test:1||Quantitative sensory testing:1||RA:1||RANKJNK signaling:1||RHEUMATIC DISEASES:1||RHEUMATOID ARTHRITIS:1||RUNX2:1||Radiographic progression:1||Restooping:1||Recommendations:1||Registries:1||Registry:1||Remission:1||Renal insufficiency:1||Response:1||Risk:1||Risk factor:1||SAPHO syndrome:1||SEX:1||SKI306X:1||SKIN TEST:1||SMURF1:1||SOX9:1||STAT3 phosphorylation inhibition:1||SYMPHYSIS PUBIS:1||Sacroiliitis:1||Sacrum:1||Scleroderma:1||Seropositive rheumatoid arthritis:1||Signal transducer and activator of transcription:1||Skeletal muscle:1||Sleep:1||Smad1:1||Smad3:1||Smoking:1||Soft callus:1||Spinal ankylosis:1||Spine:1||Spondylarthropathies:1||Spondylitis, Ankylosing:1||Spondylitis, ankylosing:1||Spondyloarthropathies:1||Spondyloepiphyseal dysplasia tarda:1||Standardized incidence ratio:1||Steroid:1||Strengthening exercise:1||Syndesmophyte:1||Synovial Fluid:1||Synovial osteoclast precursors:1||Synovium:1||Systemic:1||Systemic onset:1||T cell:1||TGF beta 1:1||TGFbeta:1||TMEM119:1||TNF alpha:1||TNF antagonist:1||TNF blocker:1||TNF inhibitors:1||TNFalpha:1||TNFalpha blockade:1||TNFalpha blockers:1||TNFblocker:1||TNFRFc Fusion Protein:1||TUBERCULIN:1||TUBERCULOSIS:1||TUMOR NECROSIS FACTOR:1||TUMOR NECROSIS FACTOR BLOCKER:1||TUMOR NECROSIS FACTORalpha BLOCKER:1||Tapering:1||Thoracolumbar:1||Tolllike rececptor 4:1||Tomography:1||Tomosynthesis:1||Treatment response:1||Tumor Necrosis Factoralpha:1||Tumor necrosis factor inhibitors:1||Tumor necrosis factorα antagonist:1||Undifferentiated preosteoblasts:1||Undifferentiated spondyloarthropathy:1||Upadacitinib:1||Utility:1||VITAMIN D BINDING PROTEIN:1||Vaccines:1||Validation Studies:1||Vasculitis:1||Versican:1||Wnt5a:1||XRay computed:1||acetaminophen:1||acquired amegakaryocytic thrombocytopenia:1||active:1||acutephase protein:1||adalimumab:1||airway remodeling:1||alkaline phosphatase:1||angiotensinconvening enzyme:1||ankylosing spondylltis:1||ankylosis:1||anterior cruciate ligament reconstruction:1||anterior uveitis:1||antiTNF:1||antiTNF agent:1||antiTNF alpha inhibitor:1||antiprefoldin 5 antibody:1||antirheumatic agents:1||artificial intelligence:1||arylhydrocarbon receptor:1||asthma:1||autoantibody:1||autoimmune diseases:1||autoimmune hemolytic anemia:1||autoimmunity:1||bioinformatics:1||biologic therapy:1||biomarker:1||biomarkers:1||biosimilar:1||bone biochemical marker:1||bone density:1||bone remodeling:1||brodalumab:1||cervical spine:1||chondrocytes:1||chondrogenic differentiation:1||chronic:1||chronic eosinophilic inflammation:1||chronic rhinosinusitis with nasal polyps:1||cigarette smoking:1||cohort study:1||cyclooxygenase2:1||cyclosporine:1||dactylitis:1||decision tree:1||deep learning:1||differentiation:1||disease activity:1||disease progression:1||diseasemodifying antirheumatic drugs:1||dose adjustment:1||drug survival:1||effectiveness:1||enteritis:1||eosinophilderived IFNgamma:1||eosinophilderived TGF beta 1:1||epidemiology:1||erectile dysfunction:1||fat fraction:1||femur:1||forkhead box O1A (FOXO1A):1||gastrointestinal risk:1||genetics:1||herpes zoster:1||homozygosity:1||house dust mites:1||infection:1||inflammatory arthritis:1||infliximab biosimilar:1||infusion interval adjustment:1||interleukin 1:1||juvenile onset ankylosing spondylitis:1||kynurenine:1||latent tuberculosis infection:1||low back pain:1||lupus erythematosus:1||mTOR:1||metaanalysis:1||metabolic shift:1||methotrexate:1||modified Dixon:1||modified Stoke AS spinal score:1||modified stoke AS spinal score:1||modified stoke ankylosing spondylitis spinal score:1||multiple differentiation:1||musclederived cells:1||nonradiographic axial spondyloarthritis:1||nonsteroidal:1||nonradiographic axial spondyloarthritis:1||normal:1||oncedaily dosing:1||osteoarthritis:1||osteoblast differentiation:1||osteoblastic activity:1||osteoblastic differentiation:1||osteoclast:1||osteoclastogenesis:1||painful heel:1||parasite:1||patient satisfaction:1||patientreported outcomes:1||peptidyldipeptidase A:1||peripheral disease:1||phosphodiesterase type 5 inhibitor:1||physiotherapy:1||plain radiography:1||plantar heel:1||pneumonia:1||polymorphisms:1||posterior heel:1||prediction:1||prefoldin 5:1||productivity loss:1||prognosis:1||prospective study:1||protein phosphatase magnesiumdependent 1 A:1||protein phosphatase magnesiumdependent 1A (PPM1A):1||quality of life:1||randomized controlled trial:1||realworld data:1||rheumatic disease:1||runtrelated transcription factor 2 (RUNX2):1||s syndrome:1||sacroiliac joint:1||scleroderma:1||single nucleotide polymorphism:1||sinus bone cells:1||spinal damage:1||squaring:1||statistics:1||stomatognathic alignment exercise:1||sulfasalazine:1||systemic lupus erythematosus:1||temporomandibular dysfunction:1||tendonderived cells:1||trajectory modeling:1||tramadol:1||transethnic:1||transcriptome:1||treatment pattern:1||tuberculin skin test:1||type 2 diabetes mellitus:1||udenafil:1||ulcerative colitis:1||vertebral fracture:1||간질성 폐질환:1||강직성 척추염:1||건선 관절염:1||급성 횡단성 척추염:1||설문 조사:1||신경학적 증상:1||운동:1||인플릭시맙:1||전신경화증:1||.:1||지염:1||1:1||1 alpha,25dihydroxyviamin D3:1||1,25Dihydroxyviamin D3:1||1,25Dihydroxyvitamin D3:1||1,25dihydroxyvitamin D3:1||1,25D3:1||25(OH)2D3:1||2p15:1||ATLANTOAXIAL JOINT:1||AXIAL SPONDYLOARTHRITIS:1||Abatacept:1||Acute transverse myelitis:1||Adult onset Still&apos:1||Adverse event:1||Aggrecanase:1||Amino acid:1||Andersson lesion:1||Anklebrachial index:1||Anklyosis:1||Ankylosing spondylitis disease activity score (ASDAS):1||Ankylosis:1||AntiCCP antibody:1||AntiTNF:1||AntiTNF drugs:1||AntiTumor Necrosis Factor:1||Antidrug antibody:1||Antiinflammatory agents:1||Antineutrophil cytoplasmic antibody:1||Antitumor necrosis factor:1||Antitumor necrosis factor (antiTNF):1||Antibodies:1||Aortic valve insufficiency:1||Arachnoid:1||Arterial stiffness:1||Arthritis, rheumatoid:1||Aseptic abscess:1||Association:1||AtlantoAxial Joint:1||Atlantoaxial joint:1||Autoimmune Diseases:1||Autoimmune Inflammatory Rheumatic Diseases:1||BASDAI:1||BONE MINERALIZATION:1||Back pain:1||Bath Ankylosing spondylitis disease activity index (BASDAI):1||Bertolotti&apos:1||Biological product:1||Biological products:1||Biologics:1||Biomarker:1||Biomarkers:1||Bone Mineral Density:1||Bone formation:1||Bone graft:1||Bone metabolism:1||Bone morphogenetic protein 2:1||Bone morphogenetic protein receptor type 2:1||Brachydactyly:1||CC motif chemokine ligand 20:1||CFms:1||CAMK2ACREB1:1||CCL20 (CC chemokine ligand 20):1||CLASSIFICATION CRITERIA:1||COL6A1:1||COMPLEMENTARY AND ALTERNATIVE MEDICINE:1||CONVERSION:1||COPY NUMBER VARIATION:1||COVID19:1||CRSwNP:1||CYP24:1||Ca+ influx:1||Calcification:1||Cancer:1||Cartilage:1||Caspase1:1||Causespecific discontinuation:1||Cervical spine:1||Cholangiocarcinoma:1||Clinical Effectiveness:1||Clinical characteristics:1||Clonorchis sinensis:1||Cohort:1||Cohort studies:1||Copy number variations:1||Curdlanadministered SKG mice:1||Cyclooxygenase2 inhibitor:1||Cytokines:1||DAS28:1||DEPRESSION:1||DMARDs:1||DMARDs (biologic):1||Dactylitis:1||Death:1||Degenerative spinal disease:1||Depression:1||Dermatomyositis/polymyositis:1||Dihydrotestosterone:1||Dipeptidyl peptidase4 (DPP4) inhibitor:1||Disease chronicity:1||Disease progression:1||Dose tapering:1||Drug efficacy:1||Drug persistency:1||Drug retention rate:1||Dutasteride:1||Dyslipidemias:1||E148Q:1||ENTHESIS:1||ENTHESOPHYTE FORMATION:1||EQ5D:1||ER stress:1||ERAP1:1||Early diagnosis:1||Elderly:1||Enthesis:1||Enthesitis:1||Enthesitis of heel:1||Exercise:1||

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE